Cost-effectiveness of cemiplimab plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for advanced non–small cell lung cancer
This cost-effectiveness analysis suggests that CCT is a dominant first-line treatment option for aNSCLC with PD-L1 levels of at least 1% compared with PCT.
Authors
- Jingyi Zheng (ORCID: https://orcid.org/0000-0002-0393-0997)
- Surachat Ngorsuraches (ORCID: https://orcid.org/0000-0002-2327-224X)
- Jingjing Qian (ORCID: https://orcid.org/0000-0003-4624-9963)
- Xiangzhong Xue
- Brandon Johnson
Institutions
- University of South Alabama Medical Center (US)
- Auburn University (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.18553/jmcp.2025.31.2.137
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09